肝切除与复发性结直肠肝转移的肿瘤学结局改善相关:倾向匹配分析
该单中心回顾性研究纳入2003至2019年338例结直肠肝转移肝切除患者,147例(43%)出现肝内复发,中位复发时间10个月。
要点
- 肝内复发患者中位复发后总生存为29个月,再次肝切除者中位总生存41个月。
- 倾向匹配后再次肝切除组5年复发后总生存19%,单纯全身治疗组3%。
- 复发时肝病灶数目和最大病灶尺寸最能预测生存及全身治疗反应。
核心结论
- 再次肝切除联合围术期全身治疗与复发性结直肠肝转移患者复发后总生存改善独立相关。
研究设计与样本
- 回顾性单中心队列研究,2003至2019年338例结直肠肝转移肝切除患者,147例肝内复发,37例再次肝切除与37例单纯全身治疗倾向匹配。
主要发现
- 147例(43%)出现肝内复发,中位复发时间10个月,中位复发后总生存29个月。
- 再次肝切除组37例中33例(89%)接受围术期化疗。
临床怎么用
- 对肝内复发呈寡转移(病灶数目少、最大病灶小)的患者,可考虑再次肝切除并整合围术期全身治疗以改善生存。
局限性
- 回顾性单中心设计,再次肝切除组样本量小(37例),存在选择偏倚可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Following resection of colorectal liver metastasis, most patients have disease recurrence, most commonly intrahepatic. Although the role of resection in colorectal liver metastasis is well-established, there have been limited investigations assessing the benefit of repeat hepatic resection compared with systemic treatment alone for intrahepatic recurrence. METHODS: A retrospective single-institution cohort study of patients with recurrent colorectal liver metastasis following curative-intent hepatectomy was performed from 2003 to 2019. The oncologic outcomes, including post-recurrence overall survival, were evaluated using Kaplan-Meier and Cox proportional hazards modeling. Patients undergoing repeat hepatic resection were propensity-matched with patients receiving systemic treatment alone based on relevant clinicopathologic variables. RESULTS: There were 338 patients treated with hepatic resection for colorectal liver metastasis over the study period. Liver recurrence was observed in 147 (43%) patients at a median time of 10 months from prior resection, with a median post-recurrence overall survival of 29 months. There were 37 patients managed with repeat hepatic resection; 33 (89%) received perioperative chemotherapy. On propensity matching, there were no significant clinicopathologic differences between 37 patients having repeat hepatic resection and 37 patients treated with systemic treatment alone. Repeat hepatic resection was independently associated with improved 5-year post-recurrence overall survival compared with systemic treatment alone (median overall survival 41 vs 35 months, 5-year overall survival 19% vs 3%, P = .048). CONCLUSION: Disease characteristics of patients with intrahepatic recurrence of colorectal liver metastasis, specifically the number of liver lesions and size of the largest lesion, are most predictive of survival and response to systemic therapy. Patients who recur with oligometastatic liver disease experience improved outcomes and derive benefit from curative-intent repeat hepatic resection with integrated perioperative systemic therapy.
引用
- Sutton TL, Wong LH, Walker BS, et al. Hepatectomy is associated with improved oncologic outcomes in recurrent colorectal liver metastases: A propensity-matched analysis. Surgery. 2022. PMID: 36435651. doi:10.1016/j.surg.2022.10.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。